Lupin receives tentative approval from USFDA for Raltegravir Tablets
This product will be manufactured at Lupin’s Nagpur facility in India
This product will be manufactured at Lupin’s Nagpur facility in India
The centre is equipped with the most modern tools and provides an environment soothing for all professionals and patients
The new range incorporates a product that also contains the S-PRG filler employed in the Giomer range
ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM
Revenue from operations registered a growth of 12% Y-o-Y at Rs 337.63 crores for H1 FY25
JB’s domestic business continued to out-perform the market with all our major brands posting strong growth
The group plans to establish new hospitals in Kerala developing large health cities in Kochi and Kozhikode
US Generics grew 5% to Rs. 467 Crores for the quarter
Revenue growth was fueled by higher volumes and contributions from both existing and new centres
Subscribe To Our Newsletter & Stay Updated